Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies.
J AilaniE PearlmanQ ZhangA J NagyK SchuhSheena K AuroraPublished in: European journal of neurology (2019)
Galcanezumab is an option for prevention of migraine in patients who have previously failed onabotulinumtoxinA preventive therapy.